原发性肝癌免疫治疗疗效及预后预测生物标志物的研究现状  

Research status of efficacy and prognostic predictive biomarkers of immunotherapy for primary liver cancer

作　　者：刘博 石金玉 李玉 张建萍[1,2] 王楠娅 LIU Bo;SHI Jinyu;LI Yu;ZHANG Jianping;WANG Nanya(Department of Cancer,Cancer Center,the First Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]吉林大学第一医院肿瘤中心肿瘤科,长春130021 [2]长春长春市中心医院体检中心,130021

出　　处：《临床肿瘤学杂志》2023年第4期377-382,共6页Chinese Clinical Oncology

基　　金：吉林省科学技术厅科研项目计划(3D5204167428);吉林大学第一医院交叉学科课题(04034000002)。

摘　　要：原发性肝癌是全球范围内常见的致死性恶性肿瘤,在我国尤其高发。近年来,以程序性死亡受体-1(PD-1)/程序性死亡配体-1(PD-L1)抑制剂为代表的免疫治疗已成为原发性肝癌不可或缺的重要治疗手段。免疫治疗在为患者带来生存获益的同时,也面临着不同患者治疗疗效及预后差异大、原发性及继发性耐药、严重免疫相关不良反应等问题,这些问题给临床上免疫联合治疗的应用带来了巨大挑战。在原发性肝癌患者中探索疗效及预后预测生物标志物,筛选免疫治疗优势人群,对于为患者提供个体化治疗方案、改善预后至关重要。目前临床上已有多种预测性生物标志物,本文将就原发性肝癌免疫联合治疗疗效及预后预测相关生物标志物的研究现状及各标志物所面临的临床问题作一综述。Primary liver cancer is a malignant tumor with a high mortality rate worldwide,particularly in China where the incidence is especially high.In recent years,immunotherapy using programmed cell death-1(PD-1)/programmed death ligand-1(PD-L1)inhibitors has become an important and indispensable treatment for primary liver cancer.While immunotherapy has brought survival benefits to primary liver cancer patients,it also faces challenges such as varying therapeutic effects and survival among patients,primary and secondary drug resistance and some patients may experience immune-related serious adverse events.Therefore,identifying effective biomarkers to target patients who are most likely to benefit is crucial for providing individualized treatment and improving patients survival.At present,there are many predicitive biomarkers in clinical practice.At present,there are many predictive biolnarkers in clinical practice.This article reviews relevant literature on predictive biomarkers for immunotherapy of primary liver cancer.

关 键 词：原发性肝癌 免疫治疗 生物标志物 

分 类 号：R735.7[医药卫生—肿瘤]